Schizotypal traits and neuropsychological performance: The role of processing speed.


Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
09 2020
Historique:
received: 23 01 2019
revised: 17 04 2020
accepted: 27 06 2020
pubmed: 8 7 2020
medline: 22 6 2021
entrez: 8 7 2020
Statut: ppublish

Résumé

Cognitive deficits, particularly in processing speed, are widely recognized as a critical feature of schizophrenia, and are also present across schizophrenia spectrum disorders. A number of important confounders, however, such as hospitalization effects and antipsychotic medication, have been shown to affect processing speed, causing debate as to the core cognitive deficits of schizophrenia. The study of individuals who are not clinically psychotic but have schizotypal traits allows investigation of cognitive deficits associated with both positive and negative schizotypy dimensions while excluding potential confounds. A population-based community sample of 242 healthy adult volunteers assessed using the Structured Interview of Schizotypy - Revised (SIS-R) scale, and a neuropsychological testing battery that included measures of verbal ability, visual and verbal memory, verbal fluency, working memory, executive functions and processing speed. Participants were classified in High or Low Positive Schizotypy (H-PST or L-PST), High or Low Paranoia-like traits (H-PAR or L-PAR) and High or Low Negative Schizotypy (H-NST or L-NST) groups, respectively. Individuals with H-PST performed significantly (p < 0.05) worse than L-PST on measures of processing speed and executive functions. Processing speed deficits were also observed in individuals with H-PAR compared to L-PAR (p < 0.05). There were no statistically significant differences in neuropsychological performance between H-NST and L-NST on any measure. In a population-based community sample, individuals with high positive schizotypal traits or paranoia-like traits show impairments in processing speed. Consistent with a dimensional view of psychosis, this supports the hypothesis that processing speed represents a core deficit of schizophrenia-like mental states.

Sections du résumé

BACKGROUND
Cognitive deficits, particularly in processing speed, are widely recognized as a critical feature of schizophrenia, and are also present across schizophrenia spectrum disorders. A number of important confounders, however, such as hospitalization effects and antipsychotic medication, have been shown to affect processing speed, causing debate as to the core cognitive deficits of schizophrenia. The study of individuals who are not clinically psychotic but have schizotypal traits allows investigation of cognitive deficits associated with both positive and negative schizotypy dimensions while excluding potential confounds.
METHODS
A population-based community sample of 242 healthy adult volunteers assessed using the Structured Interview of Schizotypy - Revised (SIS-R) scale, and a neuropsychological testing battery that included measures of verbal ability, visual and verbal memory, verbal fluency, working memory, executive functions and processing speed. Participants were classified in High or Low Positive Schizotypy (H-PST or L-PST), High or Low Paranoia-like traits (H-PAR or L-PAR) and High or Low Negative Schizotypy (H-NST or L-NST) groups, respectively.
RESULTS
Individuals with H-PST performed significantly (p < 0.05) worse than L-PST on measures of processing speed and executive functions. Processing speed deficits were also observed in individuals with H-PAR compared to L-PAR (p < 0.05). There were no statistically significant differences in neuropsychological performance between H-NST and L-NST on any measure.
CONCLUSIONS
In a population-based community sample, individuals with high positive schizotypal traits or paranoia-like traits show impairments in processing speed. Consistent with a dimensional view of psychosis, this supports the hypothesis that processing speed represents a core deficit of schizophrenia-like mental states.

Identifiants

pubmed: 32631701
pii: S0920-9964(20)30383-2
doi: 10.1016/j.schres.2020.06.030
pmc: PMC7704687
mid: NIHMS1610520
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-134

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH066105
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors report no conflicts of interest.

Références

Am J Psychiatry. 2010 Jan;167(1):78-85
pubmed: 19952077
Arch Gen Psychiatry. 2007 May;64(5):532-42
pubmed: 17485605
Schizophr Bull. 2006 Jan;32(1):179-94
pubmed: 16166612
Addict Behav. 2014 May;39(5):994-9
pubmed: 24556155
Psychiatry Clin Neurosci. 2011 Oct;65(6):596-9
pubmed: 22003992
Am J Psychiatry. 2002 Dec;159(12):2021-6
pubmed: 12450951
Schizophr Bull. 2000;26(3):619-29
pubmed: 10993402
Cogn Neuropsychiatry. 2013;18(1-2):9-25
pubmed: 22991935
Personal Disord. 2014 Oct;5(4):413-8
pubmed: 25150366
Schizophr Res. 1999 Dec 21;40(3):201-9
pubmed: 10638858
Neurosci Biobehav Rev. 2013 Mar;37(3):317-27
pubmed: 23313650
Cogn Neuropsychiatry. 2017 May;22(3):186-212
pubmed: 28288547
J Int Neuropsychol Soc. 2007 Jul;13(4):672-82
pubmed: 17521484
Cogn Neuropsychiatry. 2005 Jan;10(1):1-33
pubmed: 16571449
Psychopathology. 2017;50(3):195-202
pubmed: 28486227
Schizophr Res. 2002 Jul 1;56(1-2):171-85
pubmed: 12084431
J Clin Exp Neuropsychol. 2016 Nov;38(9):1050-63
pubmed: 27295077
J Psychiatr Res. 2014 Jan;48(1):56-64
pubmed: 24183242
Psychiatry Res. 1998 Nov 16;81(2):241-9
pubmed: 9858040
Psychiatry Res. 2015 Aug 30;228(3):531-7
pubmed: 26117248
Schizophr Bull. 2006 Jul;32(3):525-37
pubmed: 16714471
Compr Psychiatry. 2011 Sep-Oct;52(5):511-6
pubmed: 21185555
Psychiatry Res. 2008 Nov 30;161(2):162-9
pubmed: 18849081
Arch Clin Neuropsychol. 2007 Jan;22(1):109-16
pubmed: 17161580
Psychiatry Res. 2012 Dec 30;200(2-3):635-40
pubmed: 22770765
Schizophr Res. 2005 Apr 1;74(1):43-9
pubmed: 15694753
JAMA Psychiatry. 2016 Feb;73(2):109-10
pubmed: 26720611
Schizophr Res. 2002 Mar 1;54(1-2):169-75
pubmed: 11853991
JAMA Psychiatry. 2016 Feb;73(2):129-38
pubmed: 26720073
Psychiatry Res. 2008 May 30;159(1-2):207-14
pubmed: 18423612
Schizophr Res. 1997 Aug 29;26(2-3):213-20
pubmed: 9323353

Auteurs

James Gilleen (J)

Department of Psychology, University of Roehampton, London, UK; Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. Electronic address: james.gilleen@roehampton.ac.uk.

Marcello Tesse (M)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Tjasa Velikonja (T)

Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA.

Mark Weiser (M)

Department of Psychiatry, Sheba Medical Centre, Tel Hashomer, Israel.

Michael Davidson (M)

Department of Psychiatry, Sheba Medical Centre, Tel Hashomer, Israel.

Abraham Reichenberg (A)

Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH